NCT05602142View on ClinicalTrials.gov

Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2026

Conditions
ALS
Interventions
DRUG

[11C]CPPC PET ligand

Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Johns Hopkins University

OTHER